-
公开(公告)号：EP1628967B1
公开(公告)日：2014-04-09
申请号：EP04752679.3
申请日：2004-05-19
申请人： IRM LLC
发明人： MI, Yuan , PAN, Shifeng , GRAY, Nathanael, S. , GAO, Wenqi , FAN, Yi , JIANG, Tao
IPC分类号： C07D413/10 , A61K31/4725 , C07D333/58 , C07D409/06 , C07D471/04 , C07D473/00 , C07D261/20 , C07D513/04
CPC分类号： C07D333/58 , C07D261/20 , C07D409/06 , C07D471/04 , C07D473/00 , C07D513/04
-
公开(公告)号：EP1628967A1
公开(公告)日：2006-03-01
申请号：EP04752679.3
申请日：2004-05-19
申请人： IRM LLC
发明人： MI, Yuan , PAN, Shifeng , GRAY, Nathanael, S. , GAO, Wenqi , FAN, Yi , JIANG, Tao
IPC分类号： C07D333/60
CPC分类号： C07D333/58 , C07D261/20 , C07D409/06 , C07D471/04 , C07D473/00 , C07D513/04
摘要： The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
-
公开(公告)号：EP1638551A2
公开(公告)日：2006-03-29
申请号：EP04752678.5
申请日：2004-05-19
申请人： IRM LLC
IPC分类号： A61K31/397 , A61K31/40 , A61K31/445 , A61K31/495 , A61K31/195 , A61K31/216 , C07C323/63 , C07D207/12 , C07D211/32 , C07D241/04 , C07D205/04
CPC分类号： C07C323/32 , C07C317/32 , C07C2601/14 , C07D205/04
摘要： The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
摘要翻译： 本发明涉及免疫抑制剂，其制备方法及其用途和含有它们的药物组合物。 本发明提供了一类新颖的化合物，其可用于治疗或预防由淋巴细胞相互作用介导的疾病或病症，特别是与EDG受体介导的信号转导相关的疾病。
-
公开(公告)号：EP2271645A1
公开(公告)日：2011-01-12
申请号：EP09731237.5
申请日：2009-04-03
申请人： IRM LLC
发明人： JIANG, Tao , MICHELLYS, Pierre-Yves , NGUYEN, Truc, Ngoc , PEI, Wei , WU, Baogen , ZHU, Xuefeng
IPC分类号： C07D471/04 , A61K31/519 , A61K31/53 , A61P31/00 , A61P35/00 , A61P37/00
CPC分类号： C07D471/04
摘要： The invention relates to triazine and pyrimidine derivatives having Formula (1) or (2), and methods for using such compounds. For example, the compounds of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-IR), and/or insulin receptor (InsR) or a combination thereof.
-
公开(公告)号：EP2271630A1
公开(公告)日：2011-01-12
申请号：EP09730392.9
申请日：2009-04-03
申请人： IRM LLC , Novartis AG
发明人： CHEN, Bei , JIANG, Tao , MARSILJE, Thomas, H. , MICHELLYS, Pierre-Yves , NGUYEN, Truc, Ngoc , PEI, Wei , WU, Baogen , GAO, Zhaobo , GE, Yonghui , HUANG, Chen , LI, Yuncheng , ZHU, Xuefeng
IPC分类号： C07D239/48 , C07D403/12 , C07D403/14 , C07D487/04 , A61K31/505 , A61K31/506 , A61K31/519 , A61P35/00 , A61P37/00 , A61P31/00
CPC分类号： C07D239/48 , C07D403/12 , C07D403/14 , C07D487/04
摘要： The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-1R), and/or insulin receptor (InsR) or a combination thereof.
摘要翻译： 本发明提供了新的嘧啶衍生物及其药物组合物，以及使用这些化合物的方法。 例如，本发明的嘧啶衍生物可用于治疗，改善或预防对抑制间变性淋巴瘤激酶（ALK）活性，c-ros致癌基因（ROS），胰岛素样生长因子（IGF-1R） ）和/或胰岛素受体（InsR）或其组合。
-
公开(公告)号：EP1638551B1
公开(公告)日：2011-12-21
申请号：EP04752678.5
申请日：2004-05-19
申请人： IRM LLC
IPC分类号： A61K31/397 , A61K31/40 , A61K31/445 , A61K31/495 , A61K31/195 , A61K31/216 , C07C323/63 , C07D207/12 , C07D211/32 , C07D241/04 , C07D205/04
CPC分类号： C07C323/32 , C07C317/32 , C07C2601/14 , C07D205/04
摘要： The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
-
公开(公告)号：EP2091918A2
公开(公告)日：2009-08-26
申请号：EP07864693.2
申请日：2007-11-20
申请人： IRM LLC
发明人： MICHELLYS, Pierre-Yves , PEI, Wei , MARSILJE, Thomas H. , LU, Wenshuo , CHEN, Bei , UNO, Tetsuo , JIN, Yunho , JIANG, Tao
IPC分类号： C07D213/74 , C07D239/48 , C07D239/95 , C07D401/12
CPC分类号： A61K31/506 , A61K31/5377 , A61K45/06 , C07D213/74 , C07D239/48 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D451/02 , C07D453/02 , C07D471/04 , C07D473/16 , C07D487/04 , C07D487/08
摘要： The invention provides novel pyrimidine and pyridine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 ZAP-70), insulin-like growth factor (IGF- 1R), or a combination thereof.
摘要翻译： 本发明提供了式（I）的新的嘧啶和吡啶衍生物及其药物组合物，以及使用这些化合物的方法。 例如，本发明的嘧啶和吡啶衍生物可用于治疗，改善或预防对抑制间变性淋巴瘤激酶（ALK）活性，粘着斑激酶（FAK），ζ链相关蛋白激酶70 ZAP-70），胰岛素样生长因子（IGF-1R）或其组合。
-
公开(公告)号：EP1713806B1
公开(公告)日：2013-05-08
申请号：EP05713510.5
申请日：2005-02-14
申请人： IRM LLC
发明人： CHOI, Ha-Soon , WANG, Zhicheng , GRAY, Nathanael Schiander , GU, Xiang-ju , HE, Xiaohui , HE, Yun , JIANG, Tao , LIU, YI , RICHMOND, Wendy , SIM, Taebo , YANG, Kunyong
IPC分类号： C07D471/04 , C07D487/04 , A61K31/519
CPC分类号： C07D471/04 , C07D487/04
-
公开(公告)号：EP1713806A1
公开(公告)日：2006-10-25
申请号：EP05713510.5
申请日：2005-02-14
申请人： IRM, LLC
发明人： CHOI, Ha-Soon , WANG, Zhicheng , GRAY, Nathanael Schiander , GU, Xiang-ju , HE, Xiaohui , HE, Yun , JIANG, Tao , LIU, YI , RICHMOND, Wendy , SIM, Taebo , YANG, Kunyong
IPC分类号： C07D471/04 , C07D487/04 , A61K31/519
CPC分类号： C07D471/04 , C07D487/04
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met kinases.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.012 秒)
